Belhaven Biopharma Inc. filed a Form D with the Securities and Exchange Commission on 2025-10-15.
Belhaven Biopharma Inc. filed a Form D notice of an exempt securities offering with the SEC on October 15, 2025. The filing reports $32.29M sold. Its industry group is Pharmaceuticals. It names Scott Lyman (President and Chief Executive Officer), David Neal (Chief Financial Officer and Secretary), Wes Wheeler (Director) (SEC Form D, October 15, 2025).
Is this your company?
Sell to companies like Belhaven Biopharma Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-10-15 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Belhaven Biopharma Inc.
Free to see. No signup.
More on the people and the money behind Belhaven Biopharma Inc., from the filings we hold.
Pharmaceuticals raises by companies based in North Carolina, filed within 90 days of this one, largest first.
Get an email when Belhaven Biopharma Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Belhaven Biopharma Inc. raises, hires or launches. No email unless you switch it on.
Watch Belhaven Biopharma Inc. →Get the full cited report on Belhaven Biopharma Inc.
What the filing shows about Belhaven Biopharma Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Belhaven Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives Belhaven Biopharma Inc.'s address as 84406 Winslow, Chapel Hill, NC 27517.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Belhaven Biopharma Inc. See pricing
Belhaven Biopharma Inc. is a registered filer with the SEC (CIK 1873965) and has filed since 2025-10-15. 1 filing is on record, the latest on 2025-10-15.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Belhaven Biopharma Inc.'s Form D of 2025-10-15 names Scott Lyman, David Neal, Wes Wheeler and 1 more as its officers, directors or promoters.
Its new offerings report $32.29M sold across 1 offering, as its own filings state.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
Belhaven - Needle-Free Epinephrine Nasal Spray for Fast, Reliable Allergy Emergency Relief
The title and description the site itself served, answering 200. Not a cached copy and not the company's directory entry — what was live when we asked.
On the filing as: Executive Officer, Director.
Scott Lyman is named as President and Chief Executive Officer on the Form D that Belhaven Biopharma Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
On the filing as: Executive Officer, Director.
David Neal is named as Chief Financial Officer and Secretary on the Form D that Belhaven Biopharma Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
Wes Wheeler is named as Director on the Form D that Belhaven Biopharma Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
Derek Winstanly is named as Director on the Form D that Belhaven Biopharma Inc. filed with the SEC on 15 October 2025, one of 4 people that filing names.
4 people named on the filing — 2 holding an executive role and 2 as directors only.
Named as of the 2025-10-15 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Belhaven Biopharma Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Belhaven Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Belhaven Biopharma Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Belhaven Biopharma Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Belhaven Biopharma Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-10-30 (belhavenbio.com).
Each opens in a new tab, filled in for Belhaven Biopharma Inc.. With no account yet, you sign up free and land on the result.
On these lists: Pharmaceuticals raises in Raleigh-Durham
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/belhaven-biopharma-inc-form-d-25000001